低风险甲氧西林敏感金黄色葡萄球菌菌血症短疗程与长疗程疗效相当:一项汇总队列研究
该汇总队列研究纳入3个独立回顾性队列中1995-2018年的低风险甲氧西林敏感金黄色葡萄球菌菌血症成人患者,比较短疗程(6-10天)与长疗程(11-16天)抗生素治疗的临床结局。结果显示两组90天死亡率无显著差异,且治疗时长与复发风险无关,提示低风险患者短疗程治疗可行。
要点
- 低风险MS-SAB患者短疗程(6-10天)与长疗程(11-16天)的90天死亡率无显著差异。
- 治疗时长与复发风险无关,支持在低风险患者中缩短疗程。
- 结论基于回顾性队列的汇总分析,需前瞻性研究进一步验证。
核心结论
- 在低风险甲氧西林敏感金黄色葡萄球菌菌血症患者中,短疗程抗菌治疗与长疗程相比临床结局相似。
研究设计与样本
- 汇总队列研究,纳入3个独立回顾性队列中1995-2018年的低风险MS-SAB成人患者,分别有645、219和141例。
- 采用逆概率治疗加权逻辑回归模型评估90天死亡率与治疗时长的关联。
主要发现
- 三个队列中短疗程组中位治疗时长分别为8天(IQR 7-10)、9天(IQR 8-10)和8天(IQR 7-10)。
- 长疗程组中位治疗时长分别为14天(IQR 13-15)、14天(IQR 13-15)和13天(IQR 12-15)。
- 治疗时长与复发风险无关。
临床怎么用
- 对于低风险MS-SAB患者,可考虑将抗菌治疗疗程缩短至6-10天。
- 需结合患者风险评估选择合适疗程,避免对高风险患者盲目缩短疗程。
局限性
- 研究为回顾性队列设计,可能存在未测量的混杂因素。
- 低风险人群的定义和筛选标准可能影响结果的普遍性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The recommended duration of antimicrobial treatment for Staphylococcus aureus bacteremia (SAB) is a minimum of 14 days. We compared the clinical outcomes of patients receiving short-course (SC; 6-10 days), or prolonged-course (PC; 11-16 days) antibiotic therapy for low-risk methicillin-susceptible SAB (MS-SAB). METHODS: Adults with MS-SAB in 1995-2018 were included from 3 independent retrospective cohorts. Logistic regression models fitted with inverse probability of treatment weighting were used to assess the association between the primary outcome of 90-day mortality and treatment duration for the individual cohorts as well as a pooled cohort analysis. RESULTS: A total of 645, 219, and 141 patients with low-risk MS-SAB were included from cohorts I, II, and III. Median treatment duration in the 3 SC groups was 8 days (interquartile range [IQR], 7-10), 9 days (IQR, 8-10), and 8 days (IQR, 7-10). In the PC groups, patients received a median therapy of 14 days (IQR, 13-15), 14 days (IQR, 13-15), and 13 days (IQR, 12-15). No significant differences in 90-day mortality were observed between the SC and PC group in cohort I (odds ratio [OR], 0.85 [95% confidence interval {CI}, .49-1.41]), cohort II (OR, 1.24 [95% CI, .60-2.62]), or cohort III (OR, 1.15 [95% CI, .24-4.01]). This result was consistent in the pooled cohort analysis (OR, 1.05 [95% CI, .71-1.51]). Furthermore, duration of therapy was not associated with the risk of relapse. CONCLUSIONS: In patients with low-risk MS-SAB, shorter courses of antimicrobial therapy yielded similar clinical outcomes as longer courses of therapy.
引用
- Thorlacius-Ussing L, Sandholdt H, Nissen J, et al. Comparable Outcomes of Short-Course and Prolonged-Course Therapy in Selected Cases of Methicillin-Susceptible Staphylococcus aureus Bacteremia: A Pooled Cohort Study. Clin Infect Dis. 2021. PMID: 33677515. doi:10.1093/cid/ciab201
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。